Landos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview

Landos Biopharma

08/05/2024 14:47

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected
to show no
change in quarterly revenue when it reports  results on May 10
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Landos Biopharma Inc is
for a
loss of 100 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $12.71​, below​ its last closing price of $22.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.91      -0.99     Missed  -8.2
 Sep. 30 2023  -0.84       -0.88      -0.94     Missed  -6.2
 Jun. 30 2023  -1.10       -1.10      -0.63     Beat    42.7​
 Mar. 31 2023  -0.96       -0.95      -0.90     Beat    5.3
 ​​Dec.        -1.64       -1.90      -1.30     Beat    31.6
 31 2022                                                
 Sep. 30 2022  -2.82       -2.83      -2.00     Beat    29.4​
 Jun. 30 2022  -3.75       -3.65      -2.80     Beat    23.3
 Mar. 31 2022  -3.12       -3.47      -3.70     Missed  -6.7
 This summary was machine generated May 8 at 13:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)